Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04627532 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose Study of Intravenous Infusion of PF 07304814 in Healthy Adult Participants
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT04627532 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 16 participants.
The verdict
NCT04627532, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The current study is the second clinical administration with PF-07304814, the phosphate prodrug of the active moiety PF-00835231, and the first in healthy adult participants. It is to evaluate safety, tolerability and PK of single escalating doses of PF 07304814 given as a 24-h IV infusion.
Interventions
- DRUG Placebo
- DRUG PF-07304814
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-10-23 |
| Est. Completion | 2020-12-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04627532
The ClinicalTrials.gov registry entry for NCT04627532 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04627532 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04627532 about?
NCT04627532 is a clinical study titled "Single Ascending Dose Study of Intravenous Infusion of PF 07304814 in Healthy Adult Participants". The current study is the second clinical administration with PF-07304814, the phosphate prodrug of the active moiety PF-00835231, and the first in healthy adult participants. It is to evaluate safety, tolerability and PK of single escalating doses of PF 07304814 given as a 24-h IV infusion.
What is the current status of trial NCT04627532?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2020-10-23. Estimated completion is 2020-12-17.
What interventions are being tested in trial NCT04627532?
The interventions under investigation include: Placebo (DRUG), PF-07304814 (DRUG).
Who is sponsoring clinical trial NCT04627532?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.